|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||15.34|
|Dividend & Yield||0.30 (2.34%)|
|1y Target Est||N/A|
A new drug that boosts bone formation has been shown to reduce the risk of bone fractures in women with osteoporosis, according to a study from UAB's department of medicine. “There have been limited studies comparing drugs that help build bone against drugs that work by slowing bone loss,” said Kenneth Saag, professor in the Division of Clinical Immunology and Rheumatology, in the UAB Department of Medicine, and first author of the study.
Shares of Pfizer (PFE) and Astellas Pharma (ALPMY) moved higher in morning trading Thursday after the companies said their new prostate cancer drug, Xtandi, met the main goal of an important clinical trial.
Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages. The positive data sets the stage for an earlier-than-expected approval of the drug, which is already cleared to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body.